New hope for transplant patients: gentler drug may prevent dangerous infections
NCT ID NCT06034925
Summary
This study tested whether a newer drug called maribavir works as well as the standard drug valganciclovir at preventing CMV infections in high-risk kidney transplant patients. Researchers specifically wanted to see if maribavir causes fewer serious side effects, like low white blood cell counts. The trial involved 70 adult kidney transplant recipients and compared infection rates and side effects over 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT COMPLICATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.